Related Experiment Videos
Generalized morphoea secondary to porphyria cutanea tarda
H P Stevens1, L S Ostlere, C M Black
1Department of Dermatology, Royal Free Hospital and School of Medicine, London, U.K.
The British Journal of Dermatology
|October 1, 1993
Summary
Generalized morphoea, a skin condition, was secondary to porphyria cutanea tarda in one patient. Cyclosporin treatment effectively managed these sclerodermatous skin changes, highlighting a novel therapeutic approach.
Area of Science:
- Dermatology
- Immunology
- Metabolic Disorders
Background:
- Porphyria cutanea tarda (PCT) is a metabolic disorder characterized by photosensitivity and blistering.
- Generalized morphoea is a rare autoimmune condition causing skin thickening and hardening.
- The relationship between PCT and morphoea is not well-established.
Observation:
- A patient presented with generalized morphoea.
- The patient's condition was found to be secondary to porphyria cutanea tarda.
- Sclerodermatous skin changes were observed.
Findings:
- Cyclosporin treatment led to a positive response in the patient's generalized morphoea.
- The study discusses differentiating sclerodermatous changes in PCT versus morphoea.
Implications:
- This case suggests cyclosporin as a potential treatment for morphoea secondary to PCT.
- Further research is warranted to understand the underlying mechanisms connecting PCT and morphoea.
- This finding may guide future therapeutic strategies for similar complex dermatological conditions.